BGB-A317-212

Recruiting

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors

Beigene Study ID info

BGB-A317-212

ClinicalTrials.gov ID info

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents